Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-19
2010-11-02
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S543000
Reexamination Certificate
active
07825110
ABSTRACT:
The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I,which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.
REFERENCES:
patent: 4617302 (1986-10-01), Robertson
patent: 5258510 (1993-11-01), Ogawa et al.
patent: 5559230 (1996-09-01), Ogawa et al.
patent: 5663431 (1997-09-01), Di Malta et al.
patent: 5686624 (1997-11-01), Di Malta et al.
patent: 5726322 (1998-03-01), Di Malta et al.
patent: 5728723 (1998-03-01), Di Malta et al.
patent: 5849780 (1998-12-01), Di Malta et al.
patent: 5985869 (1999-11-01), Ogawa et al.
patent: 7001898 (2006-02-01), Chen et al.
patent: 0636608 (1995-02-01), None
patent: 0640592 (1995-03-01), None
patent: 0640592 (1995-03-01), None
patent: WO 9105549 (1993-05-01), None
patent: WO 9407496 (1994-04-01), None
patent: WO 9525443 (1995-09-01), None
patent: WO 9749707 (1997-12-01), None
patent: WO 9937637 (1999-07-01), None
patent: WO 02/02531 (2002-01-01), None
patent: WO 2005/000819 (2005-01-01), None
patent: WO 2005/037795 (2005-04-01), None
patent: WO 2007/084591 (2007-07-01), None
Ali et al., Therapeutic Potential of Vasopressin Receptor Antagonists, Drugs, vol. 67, No. 6, pp. 847-858, 2007.
Van Zwieten, P.A. “Compensatory Mechanisms Associated with Congestive Heart Failure as Targets for Drug Treatment”.Progr. Pharmacol. Clin. Pharmacol, 1990, vol. 7; pp. 49-54.
Fujisawa, G. et al. “Theurapeutic Efficacy of Non-peptide ADH Antagonist OPC-31260 in SIADH rats”.Kidney Intl., 1993, vol. 44, pp. 19-23.
Ogawa, H. et al. Orally Active, Nonpeptide Vasopressin V2Receptor Antagonists: A Notel Series of 1-[4-(Benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and Related Compounds.J. Med. Chem., 1996, vol. 39, pp. 3547-3555.
Liebsch, G. et al. “Septal Vasopressin Modulates Anxiety-related behaviour in rats”.Neuroscience Letters, 1996, vol. 217, pp. 101-104.
Yatsu, T., et al., “Pharmacological Profile of YM087, a novel nonpeptide dual vasopresin V1Aand V2receptor Antagonists, in dogs”,European Journal of Pharmacology, 1997, 231, pp. 225-230, Elsevier Science B.V.
Yamamura. Y., et al.,“OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile Aquaretic Effect by Single and Multiple Oral Dosing in Rats”,The Journal of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 3, pp. 860-867, Second Tokushima Institute of New Drug Research et al., Japan.
Albright D. J., et al., 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo2,1-c-1,4] benzodiazepine-10(11H)-ylcarbonyl)-3-Orally Active Arginine Vasopressin Antagonist with Selectivity for V2Receptor,J. Med. Chem., 1998, 41, pp. 2442-2444, American Chemical Society.
Ohkawa, T. et al.; “Synthesis and Characterization of Orally Active Nonpeptide Vasopressin V2 Receptor Antagonists”. 1999,Chem. Pharm. Bull. 47(4) 501-510, Pharm. Society of Japan.
Kondo, K., et al., “7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino) benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A Potent, Orally Active Nonpeptide Arginine Vasopressin V2Receptor Antagonist”,Bioorganic&Medicinal Chemistry 7, 1999, pp. 1743-1754, Second Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., Japan.
Matschisa, A. et al., “Nonpetide Arginine Vasopressin Antagonists for Both V1Aand V2Receptor: Synthesis and Pharmacological Properties of 4′-[5-(Substituted Methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4′-{5-(Substituted Methyl)-2,3-dihydro-1H-1-benzoazepine-1-carbonyl]benzanilide Derivatives”, Pharmaceutical Society of Japan 1999,In stitute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Japan.
Ashwell, M.A., et al., “The Design, Synthesis and Physico-chemical Properties of a Novel Series of Human Vasopressin V2Receptor Antagonists”,Wyeth-Ayerst Research, Princeton, New Jersey, 2000.
Kondo, K., et al., “Novel Design of Nonpeptide AVP V2Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template”,J. Med. Chem., 2000, 43, pp. 4388-4397, American Chemical Society.
Venkatesan H., et al., Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V2 Receptor Antagonist,The Journal of Organic Chemistry, 2001, vol. 66, No. 11, pp. 3653-3661, American Chemical Society.
Xiang, M.A. et al. “Synthesis and Evaluation of Spirobenzazepines as Potent Vasopressin Receptor Antagonists”.Bioorganic&Med. Chemistry Letters, 2004, vol. 14, No. 11, Jun. 7, pp. 2987-2989. XP004841329.
Xiang, M.A. et al. “Synthesis and Evaluation of Nonpeptide Substituted Spirobenzazepines As Potent Vasopressin Antagonists”.Bioorganic&Med. Chemistry Letters, 2004, vol. 14, No. 12, Jun. 21, pp. 3143-3146. XP004841361.
Xiang, et al. “Next-Generation Spirobenzazepines: Identification of RWJ-676070 as a Balanced Vasopressin Vla/V2 Receptor Antagonist for Human Clinical Studies”.Bioorganic&Med.I Chemistry Letters, 2007, vol. 17, No. 23, pp. 6623-6628. XP022325949.
Dusza, J. P., et al., “Way-VNA-932: The First Orally Active, Nonpeptide, Vasopressin V2-Receptor Selective Agonist”,Wveth-Averst Research, Princeton, New Jersey, 2000.
Shumsky, J. S., et al., “Pyridobenzodiazepines: Synthesis and Structure-Activity Relationships of a Novel Class of Orally Active Vasopression V2Receptor”,Chemical Science Wyeth-Ayerst Research, Princeton, N.J., 2000.
Shimada, Y., et al., “4,4-Difluoro-5-Methylene-2,3,4,5-Tetrahyro-1H-1-Benzazepine Derivatives: Highly Potent and Selective Antagonist of Arginine Vasopressin V1A Receptor”, Japan Pharmaceutical Co., Ltd., Japan, 2000.
Aranapakam et al., “5-Fluoro-2-Methyl-N-[5-5H-Pyrrolo[2,1-c][1,4]Benzodiazepine-10(11H)-YL Carbonyl)-2-Pyridinyl]Benzamide (CL-385004) And Analogs As Orally Active Arginine Vasopressin Receptor Antagonists.”, Bioorg. Med. Chem. Lett., 1999, vol. 9, pp. 1737-1740.
Berge et al., “Pharmaceutical Salts.”, J. Pharm. Sci., 1977, vol. 66(1), pp. 1-19.
McCall et al., “Reactions of methyl anthranilate with ethyl γ-bromobutyrate.”, Journal of the Chemical Society (C), 1970, pp. 1126-1128, DOI: 10.1039/J39700001126.
Proctor et al., “Azabenzocycloheptenones. Part XIV. Cyclisation of amino-acid derivatives to tetrahydro-1-benzazepin-5-ones and tetrahydroquinolin-4-ones.”, J. Chem. Soc. Perkin Trans 1, 1972, vol. 14, pp. 1803-1808, DOI: 10.1039/P19720001803.
Costanzo Michael J.
Demarest Keith T.
Gunnet Joseph
Look Richard
Maryanoff Bruce
Coleman Brenda L
Janssen Pharmaceutica NV
McKown Jeremy K.
LandOfFree
Substituted spiroheterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted spiroheterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted spiroheterocycles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251997